LAB eN², a translational drug discovery accelerator established by Evotec SE and Novo Nordisk, has selected a research project led by Sloan Devlin, in collaboration with Eric Sheu at Mass General Brigham, as its first three projects. The collaboration between the groups of Sloan Devlin and Eric Sheu will examine the molecular mechanisms relating to the effects of bariatric surgery on alleviating obesity and type 2 diabetes, with the long-term goal of developing therapeutic candidates for the treatment of metabolic syndrome. Read more about the selected projects and the LAB eN² program here.